FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Austedo (deutetrabenazine) submitted by Teva Neuroscience, Inc. The approval updates the labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease
• Tardive Dyskinesia

Drugs mentioned

• AUSTEDO (deutetrabenazine)

Snippet

SUPPL AP for AUSTEDO (DEUTETRABENAZINE)